Once sufficient information is gathered on a drug, it is sent to an expert for analysis and evaluation. This process upgrades the gathered data into competitor intelligence, which is available in the form of evaluations, reviews, comments and opinions.

Currently around 2000 senior scientists working in industry and academia are commissioned to perform this evaluation process. They are overseen by more than 400 senior editorial board members. Experts are also commissioned to write reviews on research topics.

The resulting intelligence is then added in the form of:

Literature Evaluations
Provided as guides to the scientific literature, highlighting significant and important data from key references within the bibliography.

Current Opinions
The scientific and commercial significance of a drug is analyzed in the context of similar launched or investigational drugs.

Review Articles
Authoritative reviews of specific drug research topics, which survey and summarize the latest research developments.

User's Intelligence
User comments and intelligence can be added, by Intranet end-users allowing them to share internal information with colleagues.